title: [A Retrospective Analysis of Eye Disorders Due to Oxaliplatin].
abstract: In recent years, the incidence of eye disorders due to antineoplastic agents such as S-1 has increased. Eye disorders including visual field defect, visual field impairment, optic neuritis, and visual acuity reduction have been reported as serious adverse effects of oxaliplatin, an agent that is frequently used as a standard therapy for colorectal cancer. However, specific details about these conditions, such as the timing relative to oxaliplatin administration and frequencies at which they appear, remain to be clarified; therefore, we conducted a retrospective analysis of patients with eye disorders due to oxaliplatin in order to obtain evidence that would be useful in routine medical practice. Of the 55 patients who were treated with oxaliplatin in this analysis 10 (18.2%) presented with eye disorders, including blepharoptosis (5 patients, 9.1%), visual field impairment (2 patients, 3.6%), visual acuity reduction (2 patients, 3.6%), eye pain (1 patient, 1.8%), congestion (1 patient, 1.8%), watering eyes (1 patient, 1.8%), and blurred vision (1 patient, 1.8%). These symptoms appeared during the early period of treatment, such as after the first or the second dose. We found that all patients had mild symptoms (Grade 1 or 2), and most improved spontaneously. Thus, eye disorders due to oxaliplatin affect Japanese patients somewhat frequently, although the symptoms are reversible and are mild in most cases. Detailed studies that include data from a larger number of facilities should be conducted in the future.
authors.affiliation: Dept. of Pharmacy, Daini Okamoto General Hospital.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Yugo
authors.initials: Y
authors.lastname: Kawashima
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kawara
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tokuyama
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Tamura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Shimizu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced*; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010146:Pain / Q000139:chemically induced; D012189:Retrospective Studies; D014786:Vision Disorders / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin